https://mindmedicinelaw.com/briefing/fda-hearing-signals-shift-in-psychedelic-policy-and-oversight-20260928-44926The Psychedelic Journalen2026-09-28T15:05:30.613507+00:00FDA Hearing Signals Shift in Psychedelic Policy and Oversightfda hearing, psychedelic regulation, clinical trials, rescheduling, policy development, mdma, psilocybin, public health, risk mitigation, market accesshttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-reduces-cocaine-use-filament-health-s-exclusive-ip-pos-20260926-44834The Psychedelic Journalen2026-09-27T22:07:07.306503+00:00Psilocybin Clinical Trial Reduces Cocaine Use: Filament Health's Exclusive IP Positionpsilocybin clinical trial, cocaine use disorder, filament health, intellectual property, psychedelic research, substance use treatment, regulatory policy, exclusive data rights, public health, stimulant addictionhttps://mindmedicinelaw.com/briefing/mapping-5-ht2-receptor-allostery-implications-for-psychedelic-drug-design-20260925-44759The Psychedelic Journalen2026-09-27T22:08:02.915304+00:00Mapping 5-HT2 Receptor Allostery: Implications for Psychedelic Drug Design5-ht2 receptor, allosteric modulation, molecular dynamics, psychedelic drug design, serotonin receptor, signaling bias, clinical trial strategy, neuropsychiatric therapeutics, ligand efficacy, drug safetyhttps://mindmedicinelaw.com/briefing/fda-psychedelic-hearing-regulatory-signals-for-u-s-psychiatry-20260925-44835The Psychedelic Journalen2026-09-27T22:07:28.145554+00:00FDA Psychedelic Hearing: Regulatory Signals for U.S. Psychiatryfda psychedelic hearing, psychiatry regulation, clinical trial guidance, psychedelic research policy, schedule i substances, prescriber training, insurance coverage psychedelics, legal risks psychedelics, public hearing fda, psychedelic therapy compliancehttps://mindmedicinelaw.com/briefing/italy-expands-landmark-psychedelic-trial-for-depression-20260925-44836The Psychedelic Journalen2026-09-27T22:07:16.418439+00:00Italy Expands Landmark Psychedelic Trial for Depressionitaly, psychedelic clinical trials, treatment-resistant depression, regulatory policy, european union, psilocybin, public health, mental health research, trial expansion, aifahttps://mindmedicinelaw.com/briefing/psychedelic-use-and-cognitive-function-insights-from-a-2026-international-study-20260924-44726The Psychedelic Journalen2026-09-28T15:05:51.467641+00:00Psychedelic Use and Cognitive Function: Insights from a 2026 International Studypsychedelic research, cognitive function, quality of life, international study, acute effects, long-term effects, policy implications, clinical trials, mental health, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-assisted-therapy-for-major-depression-evidence-and-policy-in-brazil-20260924-44762The Psychedelic Journalen2026-09-27T22:08:38.647887+00:00Psilocybin-Assisted Therapy for Major Depression: Evidence and Policy in Brazilpsilocybin, major depressive disorder, psychedelic-assisted therapy, brazil, clinical trials, antidepressant effects, policy, adverse events, regulation, mental healthhttps://mindmedicinelaw.com/briefing/ketamine-for-adolescent-trd-clinical-promise-and-safety-gaps-20260924-44776The Psychedelic Journalen2026-09-27T22:08:29.609700+00:00Ketamine for Adolescent TRD: Clinical Promise and Safety Gapsketamine, adolescent depression, treatment-resistant depression, rapid antidepressant, long-term safety, clinical trials, pediatric psychiatry, neuroplasticity, policy implicationshttps://mindmedicinelaw.com/briefing/ayahuasca-diversity-study-reshapes-policy-and-research-standards-20260924-44793The Psychedelic Journalen2026-09-27T22:08:21.138724+00:00Ayahuasca Diversity Study Reshapes Policy and Research Standardsayahuasca, botanical diversity, chemical variability, clinical trial standardization, regulatory frameworks, public health guidance, FDA, psychedelic research, harmine, DMThttps://mindmedicinelaw.com/briefing/age-moderates-psychedelic-mental-health-outcomes-new-evidence-20260924-44723The Psychedelic Journalen2026-09-27T22:08:11.850728+00:00Age Moderates Psychedelic Mental Health Outcomes: New Evidencepsychedelic research, age moderation, mental health outcomes, clinical trial design, psilocybin, LSD, regulatory guidance, public health, mystical experience, naturalistic studyhttps://mindmedicinelaw.com/briefing/global-benchmark-approved-sud-medications-2016-2026-review-20260923-44730The Psychedelic Journalen2026-09-28T15:07:24.902192+00:00Global Benchmark: Approved SUD Medications (2016–2026) Reviewsubstance use disorder medications, umbrella review, phase 3 trials, alcohol use disorder, opioid use disorder, tobacco use disorder, real-world effectiveness, policy implications, psychedelic therapy benchmark, clinical trial outcomeshttps://mindmedicinelaw.com/briefing/psilocybin-and-music-genre-emotional-effects-in-healthy-adults-20260923-44732The Psychedelic Journalen2026-09-28T15:06:59.051875+00:00Psilocybin and Music Genre: Emotional Effects in Healthy Adultspsilocybin, music genre, emotional response, clinical trial design, psychedelic therapy, set and setting, protocol optimization, healthy volunteers, affective outcomeshttps://mindmedicinelaw.com/briefing/peripheral-biomarkers-for-ketamine-response-clinical-status-and-research-gaps-20260923-44781The Psychedelic Journalen2026-09-28T15:06:37.081144+00:00Peripheral Biomarkers for Ketamine Response: Clinical Status and Research Gapsketamine, esketamine, treatment-resistant depression, peripheral biomarkers, clinical trials, inflammatory markers, BDNF, standardization, precision psychiatry, biomarker researchhttps://mindmedicinelaw.com/briefing/psychedelics-synaptic-plasticity-and-cognitive-disorders-translational-insights--20260923-44729The Psychedelic Journalen2026-09-28T15:06:14.656538+00:00Psychedelics, Synaptic Plasticity, and Cognitive Disorders: Translational Insights for Drug Developmentsynaptic plasticity, psychedelics, cognitive disorders, neuropharmacology, clinical trial design, precision medicine, bdnf, ampakines, nmda receptor modulators, biomarkershttps://mindmedicinelaw.com/briefing/ketamine-guidelines-for-trd-va-dod-policy-versus-emerging-evidence-20260922-44782The Psychedelic Journalen2026-09-28T15:08:09.265612+00:00Ketamine Guidelines for TRD: VA/DoD Policy Versus Emerging Evidenceketamine, treatment-resistant depression, VA/DoD guidelines, clinical evidence, federal health policy, rapid antidepressant response, intravenous ketamine, mental health access, policy update, TRD researchhttps://mindmedicinelaw.com/briefing/psilocybin-for-treatment-resistant-depression-efficacy-and-safety-evidence-2026--20260922-44766The Psychedelic Journalen2026-09-28T15:07:47.094666+00:00Psilocybin for Treatment-Resistant Depression: Efficacy and Safety Evidence (2026 Review)psilocybin, treatment-resistant depression, clinical trials, psychedelic therapy, safety profile, efficacy, psychotherapeutic support, regulatory barriers, adverse events, long-term monitoringhttps://mindmedicinelaw.com/briefing/iv-ketamine-protocols-in-hospital-units-pilot-study-insights-20260921-44895The Psychedelic Journalen2026-09-28T15:08:59.098754+00:00IV Ketamine Protocols in Hospital Units: Pilot Study Insightsiv ketamine, hospital psychiatric care, pilot study, protocol implementation, public health policy, payer coverage, adverse events, multidisciplinary care, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/retraction-of-ketamine-review-alters-brain-injury-guidance-20260921-44899The Psychedelic Journalen2026-09-28T15:08:30.862406+00:00Retraction of Ketamine Review Alters Brain Injury Guidanceketamine, acute brain injury, retraction, clinical guidance, psychedelic medicine, secondary literature, peer review, neurocritical care, policy implicationshttps://mindmedicinelaw.com/briefing/first-longitudinal-study-ketamine-assisted-psychotherapy-in-youth-us-2026-20260921-44770The Psychedelic Journalen2026-09-27T22:07:40.631978+00:00First Longitudinal Study: Ketamine-Assisted Psychotherapy in Youth (US, 2026)ketamine-assisted psychotherapy, adolescents, young adults, longitudinal study, depression, suicidality, safety profile, psychedelic research, clinical trials, mental health policyhttps://mindmedicinelaw.com/briefing/psilocybin-clinical-trials-evidence-review-and-u-s-rescheduling-debate-20260918-44827The Psychedelic Journalen2026-09-27T22:07:51.796504+00:00Psilocybin Clinical Trials: Evidence Review and U.S. Rescheduling Debatepsilocybin, clinical trials, rescheduling, controlled substances act, FDA breakthrough therapy, policy implications, safety data, psychedelic therapy, regulatory frameworks